🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

32/M in excellent health. Testicular non seminomatous germ cell tumour post adequate chemo. Normal tumour markers. Plan? Approach? Sequence? Concerns?

When? - if not now..... Virendra Kumar Karthik V Sabita Jiwnani

Common post immunotherapy scene? Is neoadjuvant chemoIO making lung resection more challenging? Is this the new normal? Any increase in conversion to open surgery in your practice?

33/F, presenting with dyspnea, CECT left hemithoracic mass, mediastinal shift, biopsy- spindle cell lesion. Poor effort tolerance, no other functional work up possible. Is surgery worth going in for? Approach? Intra and Postoperative concern? #thoracicchallenges

Common post chemo immuno scene? Is this the new normal? Has using neoadjuvant chemoIO increased the rate of conversion to open lobectomy in your practice?

With the increasing use of chemoIO and a good EBUS being widely available, is mediastinoscopy a dying art? Does it still figure in our skill set as a thoracic surgeon? If so, where do you specifically use it in practice?

Surgery is the original targeted therapy! It continues to become more personalized and tailored towards biomarkers and radiographic nuances. Really nice review in AATS Journals.

Can't argue with this!

30 degree or zero degree for robotic thoracic surgery? What's your preference and why? Sabita Jiwnani Virendra Kumar Karthik V AATS ESTS

31, fit guy. Primary mediastinal germ cell tumour. Post chemotherapy, tumour markers are now normal. Surgery is his best bet. Concerns? Approach? What if bilateral phrenics are involved?

Wise words from Marc Andreessen:

Sabita Jiwnani Devayani Niyogi Somashekhar SP Manish S Bhandare arvind krishnamurthy Anand Raja 🦀 Pioneering cancer care in India 🤝Excellent opportunity for oncologists to interact with leaders of cancer surgery and care in the subcontinent. 🏖🏝 At sun kissed Goa!!

Finally! Primetime for neoadjuvant TKI in EGFR positive lung cancer? EFS/ OS data would be more conclusive. Meanwhile, the staggering difference in the MPR is what we need to work with.

Has worked really well for us in both mckeowns and ivor lewis leaks. Saved quite a few dreadful disconnections. Only prerequisite: a vascular conduit. Shravan Sharad Nadkarni ISDE.net Karthik V